

ASX ANNOUNCEMENT

23 September 2024

Date of Annual General Meeting – 20 November 2024

Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce, in accordance with Listing Rule 3.13.1, that the date of its AGM will be Wednesday 20 November 2024.

In accordance with Clarity's Constitution, the closing date for the receipt of nominations from persons wishing to be considered for election as a Director is 3 October 2024.

Shareholders will be advised of further details regarding the AGM in a separate Notice of Meeting, which will be sent to shareholders. The Notice of Meeting will also be available on the ASX Company Announcements Platform and the Company's website.

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals
Dr Alan Taylor
Executive Chairperson
ataylor@claritypharm.com

Catherine Strong
Investor/Media Relations
catherine.strong@sodali.com
+61 406 759 268

This announcement has been authorised for release by the Executive Chairperson.